EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

The Causal Relationship between PCSK9 Inhibitors and Malignant Tumors: A Mendelian Randomization Study Based on Drug Targeting

Wenxin Wang, Wei Li, Dan Zhang, Yongrun Mi, Jingyu Zhang, Guoyang He

Genes · 2024

DOI: 10.3390/genes15010132 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Genes, 2024. Verfasst von Wenxin Wang und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pathology, Xinxiang Medical University, Xinxiang 453003, China. Hauptthemen laut MEDLINE: Breast Neoplasms, Lung Neoplasms, Pharyngeal Neoplasms, Carcinoma in Situ. Die Arbeit wurde bisher 16-mal zitiert (Crossref) und nennt 41 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: the key Scientific Research Project of Henan Province Colleges and Universities, Key Scientific Research Project of Henan Province Colleges and Universities, National and Henan Province Innovation and Entrepreneurship Training Program for College Students of Xinxiang Medical University.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

This study explores the potential causal association between proprotein convertase subtilisin/kexin 9 (PCSK9) inhibitors and tumor development using Mendelian randomization (MR) based on drug targets.

Methods

Instrumental variables within ±100 kb of the PCSK9 gene locus, impacting low-density lipoprotein cholesterol (LDL-C), were utilized for MR analysis. Coronary heart disease (CHD) served as a positive control to validate the causal relationship between PCSK9 inhibitors and various cancers. We employed reverse MR to address the reverse causation concerns. Data from positive controls and tumors were sourced from OpenGWAS.

Results

MR analysis suggested a negative causal relationship between PCSK9 inhibitors and both breast and lung cancers (95%CIBreast cancer 0.81~0.99, p = 2.25 × 10−2; 95%CILung cancer 0.65~0.94, p = 2.55 × 10−3). In contrast, a positive causal link was observed with gastric, hepatic, and oral pharyngeal cancers and cervical intraepithelial neoplasia (95%CIGastric cancer 1.14~1.75, p = 1.88 × 10−2; 95%CIHepatic cancer 1.46~2.53, p = 1.16 × 10−2; 95%CIOral cavity and pharyngeal cancer 4.49~6.33, p = 3.36 × 10−4; 95%CICarcinoma in situ of cervix uteri 4.56~7.12, p = 6.91 × 10−3), without heterogeneity or pleiotropy (p > 0.05). Sensitivity analyses confirmed these findings. The results of MR of drug targets suggested no causal relationship between PCSK9 inhibitors and bladder cancer, thyroid cancer, pancreatic cancer, colorectal cancer, malignant neoplasms of the kidney (except for renal pelvis tumors), malignant neoplasms of the brain, and malignant neoplasms of the esophagus (p > 0.05). Reverse MR helped mitigate reverse causation effects.

Conclusions

The study indicates a divergent causal relationship of PCSK9 inhibitors with certain cancers. While negatively associated with breast and lung cancers, a positive causal association was observed with gastric, hepatic, oral cavity, and pharyngeal cancers and cervical carcinoma in situ. No causal links were found with bladder, thyroid, pancreatic, colorectal, certain kidney, brain, and esophageal cancers.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Breast NeoplasmsLung NeoplasmsPharyngeal NeoplasmsCarcinoma in SituFemaleHumansProprotein Convertase 9PCSK9 InhibitorsSubtilisinMendelian Randomization AnalysisProprotein Convertases

Stichwörter der Autor:innen

Mendelian randomizationPCSK9 inhibitordrug targettumor

Substanzen

PCSK9 protein, humanProprotein Convertase 9PCSK9 InhibitorsSubtilisinProprotein Convertases

Autor:innen und Institutionen

  • Department of Pathology, Xinxiang Medical University, Xinxiang 453003, China.
  • School of Forensic Medicine, Xinxiang Medical University, Xinxiang 453003, China.

Förderung

  • the key Scientific Research Project of Henan Province Colleges and Universities
  • Key Scientific Research Project of Henan Province Colleges and Universities
  • National and Henan Province Innovation and Entrepreneurship Training Program for College Students of Xinxiang Medical University

Zitieren

APA

Wang, W., Li, W., Zhang, D., Mi, Y., Zhang, J., & He, G. (2024). The Causal Relationship between PCSK9 Inhibitors and Malignant Tumors: A Mendelian Randomization Study Based on Drug Targeting. Genes. https://doi.org/10.3390/genes15010132

Vancouver

Wang W, Li W, Zhang D, Mi Y, Zhang J, He G. The Causal Relationship between PCSK9 Inhibitors and Malignant Tumors: A Mendelian Randomization Study Based on Drug Targeting. Genes. 2024. doi:10.3390/genes15010132

BibTeX
@article{Wang2024,
  author = {Wang, Wenxin and Li, Wei and Zhang, Dan and Mi, Yongrun and Zhang, Jingyu and He, Guoyang},
  title = {The Causal Relationship between PCSK9 Inhibitors and Malignant Tumors: A Mendelian Randomization Study Based on Drug Targeting},
  journal = {Genes},
  year = {2024},
  doi = {10.3390/genes15010132}
}
Kostenlos starten →